Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells

Journal of Immunology

Volumn 163, Issue 2, 1999, Pages 650-658

  Frasca, Loredana ^a   Del Porto, Paola ^a   Tuosto, Loretta ^a   Marinari, Barbara ^a   Scottà, Cristiano ^a   Carbonari, Maurizio ^a   Nicosia, Alfredo ^b   Piccolella, Enza ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR; VIRUS ANTIGEN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE COURSE; HELPER CELL; HEPATITIS C; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION;

EID: 0033565792     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.163.2.650     Document Type: Article

References (61)

1. De Magistris, M. T., J. Alexander, M. Coggeshall, A. Altman, F. C. A. Gaeta, H. M. Grey, and A. Sette. 1992. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68:625.
2. Jameson, S. C., and M. J. Bevan. 1995. T cell receptor antagonists and partial agonists. Immunity 2:1.
3. Sloan-Lancaster, J., and P. M. Allen. 1996. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in RT cell biology. Annu. Rev. Immunol. 14:1.
4. Kuchroo, V. K., J. M. Greer, D. Kaul, G. Ishioka, A. Franco, A. Sette, R. A. Sobel, and M. B. Lees. 1994. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol. 153:3326.
5. Colovai, A. I., E. Renna Molajoni, R. Cortesini, and N. Suciu-Foca. 1996. New approaches to specific immunomodulation in transplantation. Intern. Rev. Immunol. 13:161.
6. Nicholson, L. B., A. Murtaza, B. P. Hafler, A. Sette, and V. Kuchroo. 1997. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc. Natl. Acad. Sci. USA 94:9279.
7. Chang, K. M., B. Rhermann, J. G. McHutchinson, C. Pasquinelli, S. Southwood, A. Sette, and F. V. Chisari. 1997. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J. Clin. Invest. 100:2376.
8. Tsai, S.-L., Y.-M. Chen, M.-H. Chen, C.-Y. Huang, I.-S. Sheen, C.-T. Yeh, J.-H. Huang, G. C. Kuo, and Y.-F. Liaw. 1998. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 115:954.
9. Bertoletti, A., A. Sette, F. V. Chisari, A. Penna, M. Levrero, M. De Carli, M. Fiaccadori, and C. Ferrari. 1994. Natural variants of cytotoxic epitopes are T cell receptor antagonists for antiviral cytotoxic T cells. Nature 369:407.
10. Klenerman, P., S. Rowland-Jones, S. McAdam, J. Edwards, S. Daenke, D. Lallo, B. Kippe, W. Rosemberg, D. Boyd, A. Edwards, P. Giangrande, R. E. Phillips, and A. McMichael. 1994. Cytotoxic T cells activity antagonized by naturally occurring HIV-1 Gag variants. Nature 369:403.
11. Sewell, A. K., G. C. Harcourt, P. J. R. Goulder, D. A. Price, and R. E. Phillips. 1997. Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides. Eur. J. Immunol. 27:2323.
12. Kaneko, T., T. Moriyama, K. Udaka, K. Hiroishi, H. Kita, H. Okamoto, H. Yagita, K. Okumura, and M. Imawari. 1997. Impaired induction of cytotoxic T lymphocytes by antagonism of a weak borne by a variant hepatitis C virus epitope. Eur. J. Immunol. 27:1782.
13. Gilbert, S. C., M. Plebanski, S. Gupta, J. Morris, M. Cox, M. Aidoo, D. Kwiatkowski, B. M. Greenwood, H. C. Wxhittle, and A. V. S. Hill. 1998. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 279:1173.
14. Zajac, A. J., K. Murali-Krishna, J. N. Blattman, and R. Ahmed. 1998. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4 and CD8 T cells. Curr. Opin. Immunol. 10:444.
15. + T cells by primary HIV-1 infection. J. Immunol. 158:807.
16. Choo, Q. L., G. Kuo, A. I. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B hepatitis genome. Science 244:359.
17. Mondelli, M. U. 1996. Is there a role for immune responses in the pathogenesis of hepatitis C? J. Hepatol. 25:232.
18. Martell, M., J. I. Esteban, J. Quer, J. Genesca, A. Weiner, R. Esteban, J. Guardia, and J. Gomez. 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 66:3225.
19. Kurosaki, M., N. Enomoto, F. Marumo, and C. Sato. 1994. Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis. Virology 205:161.
20. Zibert, A., E. Schreier, and M. Roggendorf. 1995. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 208:653.
21. Shimizu, Y. K., H. Igarashi, T. Kiyoara, T. Cabezon, P. Farci, R. H. Purcell, and H. Yoshikura. 1996. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell culture. Virology 223:409.
22. Farci, P., H. J. Alter, D. Wong, R. H. Miller, S. Govindarjan, R. Engle, M. Shapiro, and R. H. Purcell. 1994. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. USA 91:7792.
23. Puntoriero, G., A. Meola, A. Lahm, S. Zucchelli, B. Bruni Ercole, R. Tafi, M. Pezzanera, M. U. Mondelli, R. Cortese, A. Tramontano, G. Galfré, and A. Nicosia. 1998. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J. 17:3521.
24. Farci, P., H. J. Alter, D. C. Wong, R. H. Miller, S. Govindarajan, R. Engle, M. Shapiro, and R. H. Purcel. 1994. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. USA 91:7792.
25. Del Porto, P., M. D'Amato, M. T. Fiorillo, L. Tuosto, E. Piccolella, and R. Sorrentino. 1994. Identification of a novel HLA-B27 subtype by restriction analysis of a cytotoxic γδ T cell clone. J. Immunol. 153:3093.
26. Genevée, C., A. Diu, J. Nierat, A. Caignard, P.-Y. Dietrich, L. Ferradini, S. Roman-Roman, F. Triebel, and T. Hercend. 1992. An experimentally validated panel of subfamily-specific oligonucleotide primers (Vα1-w29/Vβ1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur. J. Immunol. 22:1261.
27. Dittel, B. N., D. B. Sant'Angelo, and C. A. Janeway. 1997. Peptide antagonists inhibit the proliferation and the production of IL-4, and/or IFN-γ in T helper 1, T helper 2, and T helper O clones bearing the same TCR. J. Immunol. 158:4065.
28. Viola, A., S. Linkert, and A. Lanzavecchia. 1997. A T cell receptor (TCR) antagonist competitively inhibits serial TCR triggering by low-affinity ligands, but does not affect triggering by high-affinity anti-CD3 antibodies. Eur. J. Immunol. 27:3080.
29. Preckel, T., R. Grimm, S. Martin, and H. U. Weltzien. 1997. Altered hapten ligands antagonize trinitrophenyl-specific citotoxic T cells and block internalization of hapten-specific receptors. J. Exp. Med. 185:1803.
30. Sloan-Lancaster, J., A. S. Show, J. B. Rothbard, and P. Allen. 1994. Partial T cell signaling: altered phospho-ζ and lack of ZAP-70 recruitment in APL-induced T cell anergy. Cell 79:913.
31. Madrenas, J., R. L. Wange, J. L. Wang, N. Isakov, L. E. Samelson, and R. N. Germain. 1995. Z-phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science 267:515.
32. Southwood, S., J. Sideny, A. Kondo, M. F. del Guercio, E. Appella, S. Hoffman, R. T. Kubo, R. W. Chesnut, H. M. Grey, and A. Sette. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160:3363.
33. + T cells. J. Exp. Med. 186:757.
34. Ruppert, J., J. Alexander, K. Snoke, M. Coggeshall, E. Herbert, D. McKenzie, H. M. Grey, and A. Sette. 1993. Effect of T-cell receptor antagonism on interaction between T cells and antigen-presenting cells and on signaling events. Proc. Natl. Acad. Sci. USA 90:2671.
35. Germain, R. N. 1997. T-cell signaling: the importance of receptor clustering. Curr. Biol. 7:R640.
36. Reich, Z., J. J. Boniface, D. S. Lyons, N. Borochov, E. J. Wachtel, and M. M. Davis. 1997. Ligand-specific oligomerization of T cell receptor molecules. Nature 387:817.
37. Monks, C. R. F., B. A. Freiberg, H. Kupfer, N. Sciaky, and A. Kupfer. 1998. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395:82.
38. Valitutti, S., S. Muller, M. Cella, E. Padovan, and A. Lanzavecchia. 1995. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148.
39. Purbhoo, M. A., A. K. Sewell, P. Dlierman, P. J. R. Goulder, K. L. Hilyard, J. I. Bel, B. K. Jakobsen, and R. E. Phillips. 1998. Copresentation of natural HIV-1 agonist and antagonist ligands fails to induce the T cell receptor signaling cascade. Proc. Natl. Acad. Sci. USA 95:4527.
40. Bachmann, M. F., D. E. Speiser, A. Zakarian, and P. S. Ohashi. 1998. Inhibition of TCR triggering by a spectrum of altered peptide ligands suggests the mechanism for TCR antagonism. Eur. J. Immunol. 28:3110.
41. Lyons, D. S., A. Lieberman, J. Hampl, J. J. Boniface, Y. Chien, L. J. Berg, and M. M. Davis. 1996. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 5:53.
42. Iezzi, G., K. Karjalainen, and A. Lanzavecchia. 1998. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8:89.
43. Hammer, J., P. Valsanini, K. Tolba, D. Bolin, J. Higelin, B. Takacs, and F. Sinigaglia. 1993. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74:197.
44. Hammer, J., F. Gallazzi, E. Bono, R. W. Karr, J. Guenot, P. Valsasnini, Z. A. Nagy, and F. Sinigaglia. 1995. Peptide binding specificity of HLA-DR4 molecules: correlation with reumatoid arthritis association. J. Exp. Med. 181:1847.
45. Stern, L. J., J. H. Brown, T. S. Jardetzky, J. C. Gorga, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide Nature 368:215.
46. Wucherpfennig, K. W., and J. L. Strominger. 1995. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695.
47. Sant'Angelo, D. B., G. Waterbury, P. Preston-Hurlburt, S. T. Yoon, R. Medzhitof, S.-C. Hong, and C. A. Janeway. 1996. The specificity and orientation of a TCR to its peptide-MHC class II ligands. Immunity 4:367.
48. Colovai, A. I., Z. Liu, P. E. Harris, R. Cortesini, and N. Suciu-Foca. 1997. Allopeptide-specific T cell reactivity altered by peptide analogs. J. Immunol. 158: 48.
49. Evavold, B. D., J. Sloan-Lancaster, K. J. Wilson, J. B. Rothbard, and P. M. Allen. 1995. Specific T cell recognition of minimally homologous peptides: evidence for multiple endogenous ligands. Immunity 2:655.
50. Diepolder, H. M., R. Zachoval, R. M. Hoffmann, E. A. Wierenga, T. Santantonio, M. C. Jung, D. Eichnlaub, and G. R. Pape. 1995. Possible mechanism involving T lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346:1006.
51. + T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepathology 21:632.
52. Missale, G., R. Bertoni, V. Lamonaca, A. Valli, M. Massari, C. Mori, M. G. Rumi, M. Houghton, F. Fiaccadori, and C. Ferrari. 1996. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98:706.
53. Ferrari, C., A. Valli, L. Galati, A. Penna, P. Scaccaglia, T. Giuberti, C. Schianchi, M. G., M. G. Marin, and F. Fiaccadori. 1994. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 19:286.
54. + proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy. J. Infect. Dis. 175:1294.
55. Enomoto, N., and C. Sato. 1995. Hepatitis C virus quasispecies populations during chronic hepatitis C infection. Trends Microbiol. 3:445.
56. Booth, J. C. L., U. Kumar, D. Webster, J. Monjardino, and H. C. Thomas. 1998. Comparison of the rate of sequence variation in the hypervariable region of E2/ NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 26:223.
57. Odeberg, J., Z. Yun, A. Sonnerborg, K. Bjoro, M. Uhlen, and J. Lunderberg. 1997. Variation of hepatitis C virus hypervariable region 1 in immunocompromised patients. J. Infect. Dis. 175:938.
58. Van Doorn, L.-J., I. Capriles, G. Maertens, R. DeLeys, K. Murray, T. Kos, H. Shellekens, and W. Quint. 1995. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J. Virol. 69:773.
59. Weiner, A., A. L. Erickson, J. Kansopon, K. Crawford, E. Muchmor, A. L. Hughes, M. Houghton, and C. M. Walker. 1995. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc. Natl. Acad. Sci. USA 92:2755.
60. Hancourt, G. C., S. Garrard, M. P. Davenport, A. Edwards, and R. E. Phillips. 1998. HIV-1 variation diminishes CD4 T lymphocyte recognition. J. Exp. Med. 188:1875.
61. + T cells. Crit. Rev. Immunol. 18:569.